The Alzheimer’s Drug Discovery Foundation (ADDF) has awarded a grant of $240,000 to AgeneBio Inc. of Indianapolis, Indiana to develop a new class of small molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer’s disease.
About 15 percent of aMCI patients progress to Alzheimer’s disease. ADDF says that new research on aMCI shows that excess neural activity is associated with greater memory loss and predicts progression to Alzheimer’s disease. AgeneBio is developing therapies that are designed to selectively normalize this excess neural activity, improve memory, and slow the progression to Alzheimer’s disease.
AgeneBio’s research platform is based on the work of Michela Gallagher, founder of AgeneBio. Gallagher is Professor of Psychology and Neuroscience, and head of the Neurogentics and Behavior Center at Johns Hopkins University in Baltimore, Maryland.
RSS - Posts